LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis

Table 1 TCGA, Comparison of LincIN expression values by pathologic stages

	N	Median (1st, 3rd quartiles)	Mean (Std Dev)	P-value*
Pathologic stage (AJCC)				0.021
I (incl stage I, IA, IB)	125	0.39 (0.22, 1.76)	2.06 (4.83)
II (incl stage II, IIA, IIB)	432	0.54 (0.25, 3.75)	3.85 (8.34)
III (incl stage III, IIIA, IIIB, IIIC)	165	0.68 (0.23, 5.09)	3.92 (6.32)
IV (incl stage IV)	14	1.44 (0.28, 4.15)	4.33 (7.56)
Pathologic stage (tumor size)				0.0038
T1, <2 cm (incl T1,T1a,T1b,T1c)	199	0.40 (0.22, 3.36)	2.95 (6.85)
T2, 2-5 cm (incl T2, T2b)	443	0.54 (0.25, 4.04)	3.63 (7.10)
T3, >5 cm (incl T3)	80	0.47 (0.21, 2.41)	3.76 (9.65)
T4 (incl T4,T4b,T4d)	28	2.04 (0.63, 9.64)	6.02 (7.48)

TCGA The Cancer Genome Atlas, AJCC: American Joint Committee on Cancer
^* P value is from Kruskal-Wallis test to compare LincIN distributions within pathologic stages defined by AJCC or tumor size. This nonparametric test was used instead of one-way ANOVA due to the skewed distribution of the LincIN expression values. The samples with pathologic information stated as ‘not available' were excluded from data analysis

ISSN: 1465-542X